Total Valuation
Santhera Pharmaceuticals Holding has a market cap or net worth of $278.93M. The enterprise value is $271.86.
Market Cap$278.93M
Enterprise Value$271.86
Share Statistics
Santhera Pharmaceuticals Holding has 15,941,051 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding15,941,051
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santhera Pharmaceuticals Holding’s return on equity (ROE) is 4.17 and return on invested capital (ROIC) is -37.53%.
Return on Equity (ROE)4.17
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-37.53%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee989.55K
Profits Per Employee-631.23K
Employee Count78
Asset Turnover0.52
Inventory Turnover2.52
Valuation Ratios
The current PE Ratio of Santhera Pharmaceuticals Holding is ―. Santhera Pharmaceuticals Holding’s PEG ratio is -1.37.
PE Ratio―
PS Ratio2.12
PB Ratio-13.88
Price to Fair Value-13.88
Price to FCF-4.71
Price to Operating Cash Flow328.77
PEG Ratio-1.37
Income Statement
In the last 12 months, Santhera Pharmaceuticals Holding had revenue of 77.19M and earned -49.24M in profits. Earnings per share was -3.78.
Revenue77.19M
Gross Profit14.47M
Operating Income-37.82M
Pretax Income-49.05M
Net Income-49.24M
EBITDA-32.13M
Earnings Per Share (EPS)-3.78
Cash Flow
In the last 12 months, operating cash flow was 660.00K and capital expenditures -90.00K, giving a free cash flow of 570.00K billion.
Operating Cash Flow660.00K
Free Cash Flow570.00K
Free Cash Flow per Share0.04
Dividends & Yields
Santhera Pharmaceuticals Holding pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.40
52-Week Price Change37.08%
50-Day Moving Average22.35
200-Day Moving Average20.73
Relative Strength Index (RSI)0.07
Average Volume (3m)23.00
Important Dates
Santhera Pharmaceuticals Holding upcoming earnings date is Apr 29, 2027, TBA (Not Confirmed).
Last Earnings DateSep 30, 2026
Next Earnings DateApr 29, 2027
Ex-Dividend Date―
Financial Position
Santhera Pharmaceuticals Holding as a current ratio of 1.29, with Debt / Equity ratio of -668.64%
Current Ratio1.29
Quick Ratio0.89
Debt to Market Cap0.53
Net Debt to EBITDA-2.34
Interest Coverage Ratio-3.27
Taxes
In the past 12 months, Santhera Pharmaceuticals Holding has paid 185.00K in taxes.
Income Tax185.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Santhera Pharmaceuticals Holding EV to EBITDA ratio is -7.45, with an EV/FCF ratio of -6.87.
EV to Sales3.10
EV to EBITDA-7.45
EV to Free Cash Flow-6.87
EV to Operating Cash Flow-6.88
Balance Sheet
Santhera Pharmaceuticals Holding has $41.77M in cash and marketable securities with $41.27M in debt, giving a net cash position of $494.00K billion.
Cash & Marketable Securities$41.77M
Total Debt$41.27M
Net Cash$494.00K
Net Cash Per Share$0.03
Tangible Book Value Per Share-$5.82
Margins
Gross margin is 40.26%, with operating margin of -48.99%, and net profit margin of -63.79%.
Gross Margin40.26%
Operating Margin-48.99%
Pretax Margin-63.55%
Net Profit Margin-63.79%
EBITDA Margin-41.62%
EBIT Margin-48.99%
Analyst Forecast
The average price target for Santhera Pharmaceuticals Holding is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast126.27%
EPS Growth Forecast51.33%